---
title: "ESMO Congress 2026: Updates on ADCs, bispecifics and RIPTACs"
id: "nature-reviews-clinical-oncology-0-from-the-esmo-congress-2026"
canonical_url: "https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-0-from-the-esmo-congress-2026"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "Nature Reviews Clinical Oncology"
source_url: "https://www.nature.com/articles/s41571-026-01234-y"
published_at: "2026-11-18T12:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# ESMO Congress 2026: Updates on ADCs, bispecifics and RIPTACs
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-0-from-the-esmo-congress-2026
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** Nature Reviews Clinical Oncology
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41571-026-01234-y)
- **Published At:** 2026-11-18T12:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- The 2026 European Society of Medical Oncology (ESMO) Congress convened in Madrid and attracted clinicians, researchers and patient representatives from around the world; forty-eight presentations were co-published, and a selection are summarized in this report. - Investigators reported results from multiple trials and early-phase studies, including G-HOPE-01, which described the claudin 18.2-targeted antibody–drug conjugate **arcotatug tavatecan**; the source did not provide dosing, sample sizes, or specific efficacy metrics for this trial. - The trials **PEACE-1** and a **PROTEUS** sub-study provided additional data supporting earlier use of anti-androgen therapies; the article did not report endpoints, survival outcomes, or detailed methodology for these analyses. - Study presenters included early-phase data on **JNJ-6143**, described as a first-in-class regulated induced proximity targeting chimera (**RIPTAC**) that targets the **androgen receptor** and **bromodomain-containing protein 4** in patients with advanced castration-resistant prostate cancer; the source did not report response rates or safety results. - The PD-L1 × VEGFA bispecific antibody **pumitamig** was combined with the **B7-H3**-targeted ADC **elfetabart drozuntecan** and showed activity in patients with various advanced solid tumours according to the report; no quantitative outcomes or toxicity profiles were provided in the source. - Early-phase trials of bispecific ADCs — **HS-20122** (EGFR × MET) and **IBI3001** (EGFR × B7-H3) — yielded encouraging data per the meeting summary; the article did not include methods, cohort characteristics, or efficacy endpoints for these agents. - Phase III evidence from **TAISHAN-301** supported activity of the **B7-H3**-targeted ADC **tambotatug pelitecan** in heavily pre-treated recurrent and/or metastatic nasopharyngeal carcinoma; the source did not include numerical results, statistical analyses, or safety details. - The source is a research highlight and functions as a high-level meeting summary; many trial-specific methodological and outcome details were not reported in the article and would require access to the primary presentations or full trial publications. - The article noted broader meeting activity and referenced that a selection of the forty-eight co-published presentations are summarized elsewhere in the journal; readers needing granular trial data should consult the primary trial reports or the full conference abstracts.
## Clinical Analysis & Structured Key Points
## Your privacy, your choice We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media, as well as to allow video information to be shared for both marketing, analytics and editorial purposes. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our [privacy policy](https://www.nature.com/info/privacy) for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies Reject optional cookies [Skip to main content](https://www.nature.com/articles/s41571-026-01234-y#content) Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement [ ![Nature Reviews Clinical Oncology](https://media.springernature.com/full/nature-cms/uploads/product/nrclinonc/header-6cacb5c22900eb4634682a8eae5b788c.svg) ](https://www.nature.com/nrclinonc) * [ View all journals ](https://www.nature.com/siteindex) * [ Saved research ](https://www.nature.com/saved-research) * [ Search ](javascript:;) ## Search Search articles by subject, keyword or author Show results from All journals This journal Search [ Advanced search ](https://www.nature.com/search/advanced) ### Quick links * [Explore articles by subject](https://www.nature.com/subjects) * [Find a job](https://www.nature.com/naturecareers) * [Guide to authors](https://www.nature.com/authors/index.html) * [Editorial policies](https://www.nature.com/authors/editorial_policies/) * [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41571-026-01234-y) * [ Content Explore content ](javascript:;) ## Explore content * [ Research articles ](https://www.nature.com/nrclinonc/research-articles) * [ Reviews & Analysis ](https://www.nature.com/nrclinonc/reviews-and-analysis) * [ News & Comment ](https://www.nature.com/nrclinonc/news-and-comment) * [ Current issue ](https://www.nature.com/nrclinonc/current-issue) * [ Collections ](https://www.nature.com/nrclinonc/collections) * [Follow us on Facebook ](https://www.facebook.com/NatureReviews) * [Follow us on X ](https://twitter.com/NatRevClinOncol) * [ Subscribe ](https://www.nature.com/nrclinonc/subscribe) * [Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41571) * [ RSS feed ](https://www.nature.com/nrclinonc.rss) * [ About the journal ](javascript:;) ## About the journal * [ Aims & Scope ](https://www.nature.com/nrclinonc/aims) * [ Journal Information ](https://www.nature.com/nrclinonc/journal-information) * [ Editors ](https://www.nature.com/nrclinonc/editors) * [ Editorial policies ](https://www.nature.com/nrclinonc/editorial-policies) * [ Reviews Cross-Journal Editorial Team ](https://www.nature.com/nrclinonc/reviews-cross-journal-editorial-team) * [ Journal Credits ](https://www.nature.com/nrclinonc/journal-credits) * [ Editorial input and checks ](https://www.nature.com/nrclinonc/editorial-input-and-checks) * [ Editorial Values Statement ](https://www.nature.com/nrclinonc/editorial-values-statement) * [ Journal Metrics ](https://www.nature.com/nrclinonc/journal-impact) * [ Publishing model ](https://www.nature.com/nrclinonc/publishing-model) * [ Conferences ](https://www.nature.com/nrclinonc/conferences) * [ Web Feeds ](https://www.nature.com/nrclinonc/web-feeds) * [ Contact ](https://www.nature.com/nrclinonc/contact) * [ Publish with us ](javascript:;) ## Publish with us * [ For Authors ](https://www.nature.com/nrclinonc/for-authors) * [ For Referees ](https://www.nature.com/nrclinonc/for-referees) * [Submit manuscript ](https://mts-nrclinonc.nature.com/cgi-bin/main.plex) * [ Subscribe ](https://www.nature.com/nrclinonc/subscribe) * [ Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41571) * [ RSS feed ](https://www.nature.com/nrclinonc.rss) 1. [nature](https://www.nature.com/) 2. [nature reviews clinical oncology](https://www.nature.com/nrclinonc) 3. [research highlights](https://www.nature.com/nrclinonc/articles?type=research-highlight) 4. article * Research Highlight * Published: 18 November 2026 In the news # From the ESMO Congress 2026 * [Peter Sidaway](https://www.nature.com/articles/s41571-026-01234-y#auth-Peter-Sidaway-Aff1)[1](https://www.nature.com/articles/s41571-026-01234-y#Aff1) [_Nature Reviews Clinical Oncology_](https://www.nature.com/nrclinonc) (2026) [Cite this article](https://www.nature.com/articles/s41571-026-01234-y#citeas) Save article [ View saved research ](https://www.nature.com/saved-research) October 23–27 saw oncologists, those with related professional interests, and patients and their representatives from all over the world flock to Madrid for this year’s European Society of Medical Oncology (ESMO) Congress. This meeting has been the highlight for those with an interest in oncology research for many years, and this year’s edition did not disappoint. Forty-eight presentations were simultaneously co-published, and we highlight a selection of these elsewhere in this journal. Outside of the presidential sessions, a range of trials provided compelling results supporting those presentations, including G-HOPE-01, which described arcotatug tavatecan, another claudin 18.2-targeted ADC; and PEACE-1 and a PROTEUS sub-study, both of which provided further data on earlier use of anti-androgen therapies. The same session as the latter two studies also included promising phase I data on JNJ-6143, a first-in-class regulated induced proximity targeting chimera (RIPTAC) targeting the androgen receptor and bromodomain-containing protein 4 in patients with advanced-stage castration-resistant prostate cancer. Other novel therapies with promising data available included the combination of the PD-L1 × VEGFA bispecific antibody pumitamig with the novel B7-H3-targeted ADC elfetabart drozuntecan, which demonstrated activity in patients with various advanced-stage solid tumours, as well as similarly encouraging data on the bispecific ADCs HS-20122 (EGFR × MET) and IBI3001 (EGFR × B7-H3) from early phase trials. Phase III evidence demonstrating the efficacy of the B7-H3-targeted ADC tambotatug pelitecan was provided by the TAISHAN-301 trial, involving patients with heavily pre-treated recurrent and/or metastatic nasopharyngeal carcinoma. This is a preview of subscription content, [access via your institution](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41571-026-01234-y) ## Access options [ Access through your institution ](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41571-026-01234-y) Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 32.70 € / 30 days cancel any time [Learn more](https://shop.nature.com/products/plus/?region=ROW) Subscribe to this journal Receive 12 print issues and online access 176.64 € per year only 14.72 € per issue [Learn more](https://www.nature.com/nrclinonc/subscribe) Buy this article * Purchase on SpringerLink * Instant access to the full article PDF. 39,95 € Prices may be subject to local taxes which are calculated during checkout ### Additional access options: * [Log in](https://idp.nature.com/auth/personal/springernature?client_id=grover&redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41571-026-01234-y) * [Learn about institutional subscriptions](https://www.springernature.com/gp/librarians/licensing/license-options) * [Read our FAQs](https://support.nature.com/en/support/home) * [Contact customer support](https://www.springernature.com/gp/contact) ### Explore related subjects Discover the latest articles and news in related subjects. * [Cancer immunotherapy](https://www.nature.com/subjects/cancer-immunotherapy) * [Cancer therapeutic resistance](https://www.nature.com/subjects/cancer-therapeutic-resistance) * [Drug development](https://www.nature.com/subjects/drug-development) * [Tumour vaccines](https://www.nature.com/subjects/tumour-vaccines) ## Author information ### Authors and Affiliations 1. Nature Reviews Clinical Oncology Peter Sidaway Authors 1. Peter Sidaway [View author publications](https://www.nature.com/search?author=Peter%20Sidaway) Search author on:[PubMed](https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Peter%20Sidaway)[Google Scholar](https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Peter%20Sidaway%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en) ### Corresponding author Correspondence to Peter Sidaway. ## Rights and permissions [Reprints and permissions](https://s100.copyright.com/AppDispatchServlet?title=From%20the%20ESMO%20Congress%202026&author=Peter%20Sidaway&contentID=10.1038%2Fs41571-026-01234-y&copyright=Springer%20Nature%20Limited&publication=1759-4774&publicationDate=2026-11-18&publisherName=SpringerNature&orderBeanReset=true) ## About this article [![Check for updates. Verify currency and authenticity via CrossMark](https://www.nature.com/articles/s41571-026-01234-y)](https://crossmark.crossref.org/dialog/?doi=10.1038/s41571-026-01234-y) ### Cite this article Sidaway, P. From the ESMO Congress 2026. _Nat Rev Clin Oncol_ (2026). https://doi.org/10.1038/s41571-026-01234-y [Download citation](https://citation-needed.springer.com/v2/references/10.1038/s41571-026-01234-y?format=refman&flavour=citation) * Published: 18 November 2026 * Version of record: 18 November 2026 * DOI: https://doi.org/10.1038/s41571-026-01234-y ### Share this article Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy shareable link to clipboard Provided by the Springer Nature SharedIt content-sharing initiative [ Access through your institution ](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41571-026-01234-y) [ Buy or subscribe ](https://www.nature.com/articles/s41571-026-01234-y#access-options) ## Sections * [Author information](https://www.nature.com/articles/s41571-026-01234-y#author-information) * [Rights and permissions](https://www.nature.com/articles/s41571-026-01234-y#rightslink) * [About this article](https://www.nature.com/articles/s41571-026-01234-y#article-info) Advertisement Nature Reviews Clinical Oncology (_Nat Rev Clin Oncol_) ISSN 1759-4782 (online) ISSN 1759-4774 (print) ## nature.com footer links ### About Nature Portfolio * [About us](https://www.nature.com/npg_/company_info/index.html) * [Press releases](https://www.nature.com/npg_/press_room/press_releases.html) * [Press office](https://press.nature.com/) * [Contact us](https://support.nature.com/support/home) ### Discover content * [Journals A-Z](https://www.nature.com/siteindex) * [Articles by subject](https://www.nature.com/subjects) * [protocols.io](https://www.protocols.io/) * [Nature Index](https://www.natureindex.com/) ### Publishing policies * [Nature portfolio policies](https://www.nature.com/authors/editorial_policies) * [Open access](https://www.nature.com/nature-portfolio/for-authors/openaccess) ### Author & Researcher services * [Reprints & permissions](https://www.nature.com/reprints) * [Research data](https://www.springernature.com/gp/authors/research-data) * [Language editing](https://authorservices.springernature.com/language-editing/) * [Scientific editing](https://authorservices.springernature.com/scientific-editing/) * [Nature Masterclasses](https://masterclasses.nature.com/) * [Research Solutions](https://solutions.springernature.com/) ### Libraries & institutions * [Librarian service & tools](https://www.springernature.com/gp/librarians/tools-services) * [Librarian portal](https://www.springernature.com/gp/librarians/manage-your-account/librarianportal) * [Open research](https://www.nature.com/openresearch/about-open-access/information-for-institutions) * [Recommend to library](https://www.springernature.com/gp/librarians/recommend-to-your-library) ### Advertising & partnerships * [Advertising](https://partnerships.nature.com/product/digital-advertising/) * [Partnerships & Services](https://partnerships.nature.com/) * [Media kits](https://partnerships.nature.com/media-kits/) * [Branded content](https://partnerships.nature.com/product/branded-content-native-advertising/) ### Professional development * [Nature Awards](https://www.nature.com/immersive/natureawards/index.html) * [Nature Careers](https://www.nature.com/naturecareers/) * [Nature Conferences](https://conferences.nature.com) ### Regional websites * [Nature Africa](https://www.nature.com/natafrica) * [Nature China](http://www.naturechina.com) * [Nature India](https://www.nature.com/nindia) * [Nature Japan](https://www.natureasia.com/ja-jp) * [Nature Middle East](https://www.nature.com/nmiddleeast) * [Privacy Policy](https://www.nature.com/info/privacy) * [Use of cookies](https://www.nature.com/info/cookies) * Your privacy choices/Manage cookies * [Legal notice](https://www.nature.com/info/legal-notice) * [Accessibility statement](https://www.nature.com/info/accessibility-statement) * [Terms & Conditions](https://www.nature.com/info/terms-and-conditions) * [Your US state privacy rights](https://www.springernature.com/ccpa) [ ![Springer Nature](https://www.nature.com/oscar-static/images/logos/sn-logo-white-c8f7a9c061.svg) ](https://www.springernature.com/) © 2026 Springer Nature Limited Close banner Close ![Nature Briefing](https://www.nature.com/static/images/logos/nature-briefing-logo-n150-white-afc2e6ccc7.svg) Sign up for the _Nature Briefing_ newsletter — what matters in science, free to your inbox daily. Email address Sign up I agree my information will be processed in accordance with the _Nature_ and Springer Nature Limited [Privacy Policy](https://www.nature.com/info/privacy). Close banner Close Get the most important science stories of the day, free in your inbox. [Sign up for Nature Briefing ](https://www.nature.com/briefing/signup/?brieferEntryPoint=MainBriefingBanner) *[DOI]: Digital Object Identifier *[ISSN]: International Standard Serial Number
## Related Clinical Research

- [COMMD1 in Cancer: Dual Roles, Mechanisms, and Translational Targets](https://medichelpline.com/clinical-feed/pubmed-43059391.md) (DOI: 10.3892/or.2026.9224)
- [CD55 Is Induced by PGE2–EP4–Gi–p38 MAPK Signaling in Colorectal Cancer Cells](https://medichelpline.com/clinical-feed/pubmed-42551717.md) (DOI: 10.1016/j.gene.2026.150339)
- [Gland MRI Radiomics Predicts Time to Pathologic Progression on Prostate Cancer Active Surveillance](https://medichelpline.com/clinical-feed/medrxiv-6-automated-gland-mri-radiomics-for-predicting-time-to-pathologic-progression.md)
- [Germline genomic score P-CARE adds risk information beyond PSA for short- and long-term prostate c](https://medichelpline.com/clinical-feed/medrxiv-22-additional-value-of-germline-genomic-scores-beyond-prostate-specific-antigen.md)
- [Reassessing Breast Cancer Treatment: The Benefits of De-Escalation](https://medichelpline.com/clinical-feed/plos-medicine-0-breast-cancer-treatment-when-less-is-more.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.